Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kd Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

被引：0

作者：

Wang, Tingyu ^{[1
]}

Sun, Xiuhua ^{[2
]}

Qiu, Lihua ^{[3
]}

Su, Hang ^{[4
]}

Cao, Junning ^{[5
]}

Li, Zhiming ^{[6
]}

Song, Yuqin ^{[7
]}

Zhang, Li ^{[8
]}

Li, Dengju ^{[9
]}

Wu, Huijing ^{[10
]}

Zhang, Wei ^{[11
]}

Li, Junmin ^{[12
]}

Zhou, Keshu ^{[13
]}

Zhou, Hui ^{[14
]}

Yang, Yu ^{[15
]}

Li, Zhifeng ^{[16
,17
]}

Cen, Hong ^{[18
]}

Cai, Zhen ^{[19
]}

Zhang, Zhihui ^{[20
]}

Fu, Weijun ^{[21
]}

Jie, Jin ^{[22
]}

Li, Fei ^{[23
]}

Wu, Weixin ^{[24
]}

Gu, Xuekui ^{[25
]}

Zhu, Weiliang ^{[26
]}

Liu, Lihong ^{[27
]}

Li, Zengjun ^{[1
]}

Yi, Shuhua ^{[28
]}

Bao, Hanying ^{[29
]}

Xu, Zusheng ^{[29
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Natl Clin Res Ctr Bloo, Tianjin, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China

[4] Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China

[5] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] State Key Lab Oncol South China, Guangzhou, Peoples R China

[7] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China

[10] Hubei Canc Hosp, Wuhan, Peoples R China

[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Beijing, Peoples R China

[12] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[13] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[14] Cent South Univ, Xiangya Sch Med, Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China

[15] Fujian Med Univ, Tumor Hosp, Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[16] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China

[17] Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China

[18] Guangxi Med Univ, Tumor Hosp, Nanning, Peoples R China

[19] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[20] Sichuan Canc Hosp & Inst, Chengdu, Peoples R China

[21] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Shanghai, Peoples R China

[22] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[23] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[24] Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China

[25] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[26] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China

[27] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[28] Tianjin Inst Hlth Sci, Tianjin, Peoples R China

[29] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177820

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] The Oral PI3Kd Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Wang, Tingyu
Sun, Xiuhua
Qiu, Lihua
Su, Hang
Cao, Junning
Li, Zhiming
Song, Yuqin
Zhang, Li
Li, Dengju
Wu, Huijing
Zhang, Wei
Li, Junmin
Zhou, Keshu
Zhou, Hui
Yang, Yu
Li, Zhifeng
Cen, Hong
Cai, Zhen
Zhang, Zhihui
Fu, Weijun
Jin, Jie
Li, Fei
Wu, Weixin
Gu, Xuekui
Zhu, Weiliang
Liu, Lihong
Li, Zengjun
Yi, Shuhua
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1440 - 1449
[2] PI3K δ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
Su, Hang
Wang, Tingyu
Sun, Xiuhua
Qiu, Lihua
Cao, Junning
Li, Zhiming
Song, Yuqin
Zhang, Li
Li, Dengju
Wu, Huijing
Zhang, Wei
Li, Junmin
Zhou, Keshu
Zhou, Hui
Yang, Yu
Li, Zhifeng
Cen, Hong
Cai, Zhen
Zhang, Zhihui
Fu, Weijun
Jie, Jin
Li, Fei
Wu, Weixin
Gu, Xuekui
Zhu, Weiliang
Liu, Lihong
Li, Zengjun
Yi, Shuhua
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
BLOOD, 2023, 142
[3] A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China
Zheng, Zhong
Zhang, Huilai
Wang, Jingwen
Zhou, Keshu
Zhang, Li
Zhou, Hui
Zhang, Qingyuan
Zhao, Weili
BLOOD, 2021, 138
[4] Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
Trneny, Marek
Avigdor, Abraham
Mckinney, Matthew S.
Paneesha, Shankara
Wahlin, Bjorn E.
Hrom, John S.
Cunningham, David
Morley, Nicholas
Canales, Miguel
Bastos-Oreiro, Mariana
Belada, David
Devizzi, Liliana
Zheng, Fred
Demarini, Douglas J.
Jiang, Wei
Jiang, Ping
Lynch, Ryan C.
ECLINICALMEDICINE, 2023, 63
[5] Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Li, Zhiming
Yang, Haiyan
Cen, Hong
Huang, Rui
Cai, Zhen
Gu, Xuekui
Bao, Hanying
Xu, Zusheng
Xu, Zuhong
BLOOD, 2021, 138
[6] Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre single-arm, phase 2 trial
Alderuccio, Juan Pablo
Alencar, Alvaro J.
Schatz, Jonathan H.
Kuker, Russ A.
Pongas, Georgios
Reis, Isildinha M.
Lekakis, Lazaros J.
Spiegel, Jay Y.
Sandoval-Sus, Jose
Beitinjaneh, Amer
Stanchina, Michele D.
Trabolsi, Asaad
Lossos, Izidore S.
Rosenblatt, Joseph D.
Lessen, David S.
Moskowitz, Craig H.
LANCET HAEMATOLOGY, 2025, 12 (01): : e23 - e34
[7] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Morschhauser, Franck
Tilly, Herve
Chaidos, Aristeidis
McKay, Pamela
Phillips, Tycel
Assouline, Sarit
Batievi, Connie Lee
Campbell, Phillip
Ribrag, Vincent
Damaj, Gandhi Laurent
Dickinson, Michael
Jurczak, Wojciech
Kazmierczak, Maciej
Opat, Stephen
Radford, John
Schmitt, Anna
Yang, Jay
Whalen, Jennifer
Agarwal, Shefali
Adib, Deyaa
Salles, Gilles
LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
[8] Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
Zinzani, Pier Luigi
Trneny, Marek
Ribrag, Vincent
Zilioli, Vittorio Ruggero
Walewski, Jan
Christensen, Jacob Haaber
Delwail, Vincent
Rodriguez, Guillermo
Venugopal, Parameswaran
Coleman, Morton
Dartigeas, Caroline
Patti, Caterina
Pane, Fabrizio
Jurczak, Wojciech
Taszner, Michal
Paneesha, Shankara
Zheng, Fred
Demarini, Douglas J.
Jiang, Wei
Gilmartin, Aidan
Mehta, Amitkumar
ECLINICALMEDICINE, 2023, 62
[9] PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Sun, Peng
Cen, Hong
Yang, Haiyan
Huang, Rui
Cai, Zhen
Gu, Xuekui
Bao, Hanying
Xu, Zusheng
Xu, Zuhong
Li, Zhi-Ming
CANCER CELL INTERNATIONAL, 2025, 25 (01)
[10] A Phase1b Clinical Study of the Oral PI3Kd Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas
Qiu, Lugui
Li, Zhiming
Huang, Yunhong
Liu, Ligen
Liu, Lihong
Guo, Ye
Deng, Lan
Yang, Haiyan
CA, Zhen, I
Ye, Xu
Wang, Zhen
Bao, Hanying
Xu, Zusheng
Zheng, Binghua
BLOOD, 2021, 138

← 1 2 3 4 5 →